Clinical Trial Detail

NCT ID NCT03596866
Title An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib (ALTA-3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Ariad Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Brigatinib

Alectinib

Age Groups: adult senior

Additional content available in CKB BOOST